Interleukin-13 Antibody Composition
AssigneeMedlmmune, LLC
InventorsClaire Louise Hope, Karen Bannister, Brendan Cormack Fish, Jeanette Elizabeth Langstone
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma.
Claims25
A pharmaceutical composition comprising an IL-13 antibody and one or more pharmaceutically acceptable excipients buffered to a pH of 4.5-6.0 with acetate buffer.
A pharmaceutical composition as defined in any preceding claims which is buffered to a pH of 5.2 to 5.7
A pharmaceutical composition as defined in any preceding claims which comprises sodium acetate present within the pharmaceutical composition in an amount of between 1 and 100 mM.
A pharmaceutical composition as defined in any preceding claims wherein the pharmaceutically acceptable excipient comprises one or more surfactant, inorganic or organic salt, stabilizer, diluent, solubilizer, reducing agent, antioxidant, chelating agent and/or preservative.
A process for purifying an IL-13 antibody which comprises one or more chromatographic separation steps wherein each of said separation steps comprises elution with an elution buffer comprising one or more pharmaceutically acceptable excipients buffered to a pH of 3.5-7.0 with acetate buffer.
Dependencies are inferred from the claim text.